Literature DB >> 18309251

[Dissemination of IMP-1 and OXA type beta-lactamase in carbapenem-resistant Acinetobacter baumannii].

Ji Youn Sung1, Kye Chul Kwon, Jong Woo Park, Yeon Suk Kim, Ji Myung Kim, Kyeong Seob Shin, Jong Wan Kim, Chi Seon Ko, So Youn Shin, Jeong Hoon Song, Sun Hoe Koo.   

Abstract

BACKGROUND: Acinetobacter baumannii is an aerobic, gram-negative, glucose-nonfermenting bacterium, which has emerged as a serious opportunistic pathogen. In recent years, the increasing instance of carbapenem-resistant A. baumannii producing metallo-beta-lactamases (MBLs) or OXAtype beta-lactamases is causing a serious clinical problem. In this study, we investigated the prevalence of Ambler class A, B, and D beta-lactamases and their extended-spectrum derivatives in carbapenem-resistant A. baumannii isolates.
METHODS: A total of 31 consecutive, non-duplicate, carbapenem-resistant A. baumannii were isolated from three university hospitals in the Chungcheong province of Korea. The modified Hodge and inhibitor-potentiated disk diffusion tests were conducted for the screening of carbapenemase and MBL production, respectively. PCR and DNA sequencing were performed for the detection of beta-lactamase genes. We also employed the enterobacterial repetitive intergenic consensus (ERIC)-PCR method for the epidemiologic study.
RESULTS: Twenty-three of 31 isolates harbored bla(OXA-2)(51.6%), bla(OXA-23)(22.6%), bla(IMP-1)(48.4%),and bla(VIM-2)(3.2%). All of the OXA-2-producing strains also evidenced MBLs. The strains that harbored bla(OXA-23)were isolated only in hospital C, and only in a limited fashion. The ERIC-PCR pattern of the five OXA-23 strains indicated that the isolates were closely related in terms of clonality. The six strains producing IMP-1 isolated from hospital A were confirmed to be identical strains.
CONCLUSIONS: A. baumannii strains harboring IMP-1 or OXA-type beta-lactamases are currently widely distributed throughout the Chungcheong province of Korea. The most notable finding in this study was that a bla(OXA-2)-producing A. baumannii harboring MBL, which has not been previously reported, can also lead to outbreaks.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18309251     DOI: 10.3343/kjlm.2008.28.1.16

Source DB:  PubMed          Journal:  Korean J Lab Med        ISSN: 1598-6535


  6 in total

1.  Drug-resistant gene of blaOXA-23, blaOXA-24, blaOXA-51 and blaOXA-58 in Acinetobacter baumannii.

Authors:  Chenggong Hou; Feng Yang
Journal:  Int J Clin Exp Med       Date:  2015-08-15

2.  Antimicrobial resistance determinants in imipenem-nonsusceptible Acinetobacter calcoaceticus-baumannii complex isolated in Daejeon, Korea.

Authors:  Ji Youn Sung; Kye Chul Kwon; Hye Hyun Cho; Sun Hoe Koo
Journal:  Korean J Lab Med       Date:  2011-10-03

Review 3.  Multidrug-resistant Acinetobacter spp.: increasingly problematic nosocomial pathogens.

Authors:  Kyungwon Lee; Dongeun Yong; Seok Hoon Jeong; Yunsop Chong
Journal:  Yonsei Med J       Date:  2011-11       Impact factor: 2.759

4.  Usefulness of phenotypic and genotypic methods for metallo-beta-lactamases detection in carbapenem-resistant Acinetobacter baumannii strains.

Authors:  Aleksandra Szejbach; Agnieszka Mikucka; Tomasz Bogiel; Eugenia Gospodarek
Journal:  Med Sci Monit Basic Res       Date:  2013-01-21

5.  Prevalence and Genetic Characterization of Carbapenem- and Polymyxin-Resistant Acinetobacter baumannii Isolated from a Tertiary Hospital in Terengganu, Malaysia.

Authors:  Soo-Sum Lean; Zarizal Suhaili; Salwani Ismail; Nor Iza A Rahman; Norlela Othman; Fatimah Haslina Abdullah; Zakaria Jusoh; Chew Chieng Yeo; Kwai-Lin Thong
Journal:  ISRN Microbiol       Date:  2014-03-19

6.  Characterization of Oxacillinase and Metallo-β-Lactamas Genes and Molecular Typing of Clinical Isolates of Acinetobacter baumannii in Ahvaz, South-West of Iran.

Authors:  Saeed Shoja; Mojtaba Moosavian; Soodabeh Rostami; Fariba Abbasi; Mohammad Amin Tabatabaiefar; Amir Peymani
Journal:  Jundishapur J Microbiol       Date:  2016-02-13       Impact factor: 0.747

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.